Analyst Ratings For Protagonist Therapeutics (NASDAQ:PTGX)
Today, BMO Capital Markets lowered its price target on Protagonist Therapeutics (NASDAQ:PTGX) to $42.00 per share.
Some recent analyst ratings include
- 1/29/2018-Stifel Nicolaus initiated coverage with a Buy rating.
- 7/21/2017-BTIG Research initiated coverage with a Buy rating.
- 9/6/2016-Leerink Swann initiated coverage with a Outperform rating.
- 9/6/2016-Barclays initiated coverage with a Overweight rating.
Recent Insider Trading Activity For Protagonist Therapeutics (NASDAQ:PTGX)
Protagonist Therapeutics (NASDAQ:PTGX) has insider ownership of 15.50% and institutional ownership of 57.77%.
- On 3/2/2018 David Y Liu, Insider, sold 875 with an average share price of $20.00 per share and the total transaction amounting to $17,500.00.
- On 1/16/2018 David Y Liu, Insider, sold 875 with an average share price of $20.00 per share and the total transaction amounting to $17,500.00.
- On 12/22/2017 Richard S Shames, Insider, sold 3,529 with an average share price of $20.50 per share and the total transaction amounting to $72,344.50.
- On 12/20/2017 Dinesh V Ph D Patel, Insider, sold 1,790 with an average share price of $19.55 per share and the total transaction amounting to $34,994.50.
- On 12/18/2017 David Y Liu, Insider, sold 875 with an average share price of $20.00 per share and the total transaction amounting to $17,500.00.
- On 12/18/2017 Thomas P O’neil, CFO, sold 8,000 with an average share price of $20.00 per share and the total transaction amounting to $160,000.00.
- On 11/30/2017 David Y Liu, Insider, sold 875 with an average share price of $20.00 per share and the total transaction amounting to $17,500.00.
Recent Trading Activity for Protagonist Therapeutics (NASDAQ:PTGX)
Shares of Protagonist Therapeutics closed the previous trading session at 20.86 down -0.03 0.14% with shares trading hands.
